| Document |
Document Title |
|
WO/2006/080509A1 |
A novel pyrimidine nucleoside compound, or its salt, of the general formula: (1) wherein one of X and Y is a cyano while the other is a hydrogen atom; and one of R1 and R2 is a hydrogen atom, a carbonyl having an alkyl monosubstituted wi...
|
|
WO/2006/077816A1 |
The invention relates to a novel imidazo[4,5-b]pyridine derivative compound represented by the formula (I) and a pharmaceutically acceptable salt thereof. The invention also relates to a method of producing the compound. The invention fu...
|
|
WO/2006/078752A2 |
The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.
|
|
WO/2006/075993A2 |
Disclosed are adenosine derivatives, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
|
|
WO/2006/076102A2 |
The present invention provides fluorescent nucleoside analogs with conjugated membered heterocycles, including furan and thiophene. The fluorescent nucleoside analogs maintain structural similarity to naturally occurring nucleoside bases...
|
|
WO/2006/074416A1 |
The present invention provides a method for increasing the efficacy of antifolates which act via inhibition of dihydrofolate reductase (DHFR). The method comprises the steps of administration of 5-amino-4-imidazolecarboxarnide riboside (...
|
|
WO/2006/070985A1 |
This invention relates to an improved method for stereoselectively preparing 2´-deoxy-2´,2´-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase of fo...
|
|
WO/2006/071090A1 |
This invention relates to an improved method for stereoselectively preparing 2¢¥-deoxy-2¢¥,2¢¥-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase...
|
|
WO/2006/066439A2 |
Nucleic acid sequence analogues, in particular tRNA analogues comprising in the place of a 3'-terminal adenosine a 3'-terminal 2'-deoxy-2'-thioadenosine are able to react site-specifically with weakly activated amino acid derivatives (e....
|
|
WO/2006/066074A2 |
Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or lycerol phosphate ethers.
|
|
WO/2006/065525A1 |
The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using.
|
|
WO/2006/063717A2 |
The present invention concerns methods of polymerase independent template directed elongation of polynucleotides, nucleotide building blocks used in these methods as well as the use of the methods and building blocks for the determinatio...
|
|
WO/2006/062434A1 |
The invention relates to molecular biology, virology and medicine, in particular to novel 3'azido-3'-dezoxythymidine-phosphonates of general formula (I), wherein R is alkyl groups including groups containing halogen atoms, carboxy, hydro...
|
|
WO/2006/063105A1 |
A stereoselective process for the preparation of a 2’,2’-difluronucleoside is provided. In the process, a protected 2’,2’-difluorofuranose is coupled with a base selected from the group consisting of pyrimidine and purine derivat...
|
|
WO/2006/060617A1 |
The present invention provides novel crystalline forms of ascomycin as well as processes for the preparation thereof and pharmaceutical compositions comprising such crystalline forms of ascomycin.
|
|
WO/2006/060615A1 |
An amorphous pimecrolimus and processes for providing an amorphous pimecrolimus are provided.
|
|
WO/2006/058796A2 |
The invention relates to a method for making osyl and hexoses derivatives of formula (1), especially 2-fluoro-2-deoxy derivatives, wherein R is a nucleoside such as adenosine, cytidine, guanosine, uridine and deoxy analogs such as 2-deox...
|
|
WO/2006/060616A1 |
The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus.
|
|
WO/2006/045616A2 |
The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caus...
|
|
WO/2006/040111A2 |
A process for the production of 33-Epi-33-chloro-FR 520 in one step from FR520 wherein protecting groups are avoided.
|
|
WO/2006/040558A1 |
This invention relates to compounds of Formula (I): and their use in the treatment of bacterial infections.
|
|
WO2006015357A9 |
The invention provides compounds having the following general formula (I): wherein X, R
|
|
WO/2006/038865A1 |
The present invention relates to novel nucleotides and to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament. More particularly, the present in...
|
|
WO/2006/035796A1 |
A compound having SGLT1 and/or SGLT2 inhibitory activity which is usable as a preventive or therapeutic agent for diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, etc. It is a 1-(β-D-...
|
|
WO/2006/037024A2 |
The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administer...
|
|
WO/2006/033709A2 |
Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and oth...
|
|
WO/2006/032087A1 |
The invention relates generally to virus resistant plants, wherein the plants are resistant to aphid transmitted viruses. In particular, the invention relates to a method for protecting a plant from aphid-borne viral infection, comprisin...
|
|
WO/2006/034154A2 |
The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of admi...
|
|
WO/2006/032921A1 |
The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally ...
|
|
WO/2006/030803A1 |
A purinenucleoside derivative modified in the 8-position which is useful for diseases attributable to abnormality in plasma uric acid level. It is a purinenucleoside derivative modified in the 8-position which is represented by the follo...
|
|
WO/2006/030980A1 |
It is intended to provide an agent and a food for preventing/improving functional digestive disorder which contains, as the active ingredient, at least one member selected from among glutamic acid, 5’-nucleotides and salts thereof.
|
|
WO/2006/028618A1 |
The invention provides compounds having the following general formula (I) wherein X, R1, R2, R7 and Z are as described herein.
|
|
WO/2006/029065A1 |
Disclosed are prodrugs of inactivators of 06-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the (3-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrug...
|
|
WO/2006/026651A1 |
Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, a...
|
|
WO/2006/026656A1 |
The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation a...
|
|
WO/2006/025154A1 |
The invention aims at providing oligonucleotides modified at the 3' end which are excellent in penetration through cell membrane, resistance to nuclease, and the ability to form double strands and whose production was difficult in the pr...
|
|
WO/2006/022323A1 |
Disclosed is a novel phosphoramidite compound which is useful for synthesis of an oligo-RNA. Specifically disclosed is a phosphoramidite compound represented by the following general formula (1). [In the formula, Bx represents a nucleic ...
|
|
WO2005026184A9 |
The invention provides compositions the comprise nucleotides and/or nucleosides having blocking groups at 2'-positions of sugar moieties. Methods of synthesizing these nucleic acids are also provided.
|
|
WO/2006/023272A1 |
The invention provides compounds having the following general formula (I) wherein X, R1, R2, R7 and Z are as described herein.
|
|
WO/2006/021341A1 |
4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-diyhdroxy-5-hydroxymeth
yl-tetrahydrofuran-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for ...
|
|
WO/2006/020712A1 |
A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
|
|
WO/2006/017052A1 |
Disclosed is a synthesis suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists having the structure of formula (I), wherein R is optionally substituted phenyl, that are useful fo...
|
|
WO/2006/014387A1 |
Orthogonally protected 3'-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3'-amino group in the presence of the unprotected nucleoside base.
|
|
WO2005111056B1 |
Novel esters of adenosine nucleosides and carboxylic acid, of formula 1, wherein R
|
|
WO/2006/005064A2 |
Compositions and methods for detecting 5-methylcytosine in a nucleic acid are disclosed. A 5-methylcytosine discriminator, which is a deoxyribonucleosidetriphosphate comprising a cytosine-pairing moiety such as a guanosine and a moiety w...
|
|
WO/2006/000883A2 |
This invention relates to an improved process for the industrial manufacture of S-adenosyl-L-methionine (SAMe) of Formula (I), which consists of stereo-selective methylation of S-adenosyl-L-homocysteine (SAH) Formula (II) with the enrich...
|
|
WO/2005/123755A2 |
This invention provides novel 8-carbyl substituted Camps (adenosine 3′, 5′-cyclic monophosphorothioate) and a novel procedures for the preparation of 8-Br-cAMP, a key starting material.
|
|
WO/2005/121361A2 |
The present invention relates to a method for detecting sequence specific methylation in a biomolecule, comprising: (a) contacting a biomolecule with an S-adenosyl-L-methionine-dependent methyltransferase in the presence of a detectable ...
|
|
WO/2005/121162A1 |
The invention is directed to 3-ß-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or pr...
|
|
WO/2005/117910A2 |
The invention relates to Purine Derivatives, compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal’s rate of metabolism, protecting an animal’s heart against myocardial damage during c...
|
